Artifa’s Allonk: Unprecedented Lupus Breakthrough
Artiva Biotherapeutics has begun a Phase 1 trial of its AlloNK (AB-101) cell therapy in combination with monoclonal antibodies...
Unpacking FDA’s Discussion Paper on AI in Clinical Trials
In a pioneering initiative, the Food and Drug Administration (FDA) has laid out a comprehensive discussion paper focusing on...
Precision Biosciences’ Programs Make a Stunning Return: Collaboration with Prevail Therapeutics Concludes
Precision BioSciences has regained control of three gene editing programs from Prevail Therapeutics, a subsidiary of Eli Lilly. The...
Medincell’s Partnership with AbbVie: Unlocking Next-Gen Injectable Therapies
Medincell has teamed up with AbbVie to develop and commercialize up to six innovative long-acting injectable (LAI) therapies. This...
Calidi Biotherapeutics IPO Raises $6.1 Million
Calidi Biotherapeutics, a biotechnology company focused on developing targeted immunotherapies, has priced its public offering for 15,197,500 shares of...
Biotech Asher Secures $55 Million Funding: Phase 1B Trials on the Horizon
Asher Biotherapeutics, a leader in developing targeted immunotherapies, has secured $55 million in Series C funding led by RA...
Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib
Volastra Therapeutics has advanced its clinical-stage KIF18A inhibitor, sovilnesib, into Phase Ib clinical trials. The trials will evaluate the...
Spikimm, Satt Conectus Join Forces for Innovative BK Virus Treatment
SpikImm, a biotech company established in 2021, has entered an exclusive agreement with SATT Conectus for the development of...
How Do In Silico Trials Work? A Brief Guide
In silico methodologies have transformed the landscape of drug development, providing a virtual platform to predict and optimize drug...
New Insights: International Clinical Trial Regulatory Innovation
At the recent Duke-Margolis Institute for Health Policy conference, regulatory experts worldwide gathered to discuss advancements and collaborative strategies...